| 000 | 01521 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515190944.0 | ||
| 264 | 0 | _c20100419 | |
| 008 | 201004s 0 0 ger d | ||
| 022 | _a1433-0563 | ||
| 024 | 7 |
_a10.1007/s00120-009-2109-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRinghoffer, M | |
| 245 | 0 | 0 |
_a[Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy]. _h[electronic resource] |
| 260 |
_bDer Urologe. Ausg. A _cNov 2009 |
||
| 300 |
_a1308-17 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 |
_aInterleukin-2 _xadverse effects |
| 650 | 0 | 4 |
_aIntracellular Signaling Peptides and Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTOR Serine-Threonine Kinases |
| 700 | 1 | _aRinnab, L | |
| 700 | 1 | _aKüfer, R | |
| 700 | 1 | _aGreiner, J | |
| 773 | 0 |
_tDer Urologe. Ausg. A _gvol. 48 _gno. 11 _gp. 1308-17 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00120-009-2109-y _zAvailable from publisher's website |
| 999 |
_c19201454 _d19201454 |
||